000850854 001__ 850854
000850854 005__ 20210129234640.0
000850854 0247_ $$2doi$$a10.3389/fneur.2018.00627
000850854 0247_ $$2Handle$$a2128/19476
000850854 0247_ $$2WOS$$aWOS:000440198900001
000850854 0247_ $$2altmetric$$aaltmetric:45820862
000850854 0247_ $$2pmid$$apmid:30105000
000850854 037__ $$aFZJ-2018-04614
000850854 082__ $$a610
000850854 1001_ $$0P:(DE-HGF)0$$aEggers, Carsten$$b0$$eCorresponding author
000850854 245__ $$aAccess to End-of Life Parkinson's Disease Patients Through Patient-Centered Integrated Healthcare
000850854 260__ $$aLausanne$$bFrontiers Research Foundation$$c2018
000850854 3367_ $$2DRIVER$$aarticle
000850854 3367_ $$2DataCite$$aOutput Types/Journal article
000850854 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533102028_30756
000850854 3367_ $$2BibTeX$$aARTICLE
000850854 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000850854 3367_ $$00$$2EndNote$$aJournal Article
000850854 520__ $$aBackground: Palliative care in Parkinson's Disease (PD) patients considerably differs from palliative care in oncology patients. Integrated care models are a concept to support patients and improve management of PD symptoms. However, it is not known if the access to PD patients at the end of life can be achieved through integrated care models.Aim: To analyze an integrated model of care for PD patients with the aim to identify if this integrated model of care has access to PD patients at the end of life.Material and Methods: The Cologne Parkinson's network was designed as a randomized, controlled prospective clinical trial in order to increase quality of life of PD patients. This innovative model of care integrated a neurologist in private practice, a movement disorder specialist of the University Hospital and a PD nurse. Mortality rates of PD patients during the study period of 6 months were registered and compared with mortality rates of the general population of Germany according to the Federal Statistical Office of Germany. The retrospective post-hoc analysis was conducted after completion of the initial study at the University Hospital and neurologists' practices in the greater area of Cologne, Germany. Eligible patients had a diagnosis of idiopathic PD and were aged 25–85 years.Results: Parkinson's Disease patients in this trial had an even slightly lower mortality rate as the general population (1.66 v. 2.1%). These results are contradictory and speak for a substantial proportion of late-stage disease patients, who have not been adequately included in this study or have been better treated within this trial. The mean disease duration of patients in this study was around 6 years which resembles the lower range of the mean disease duration at death of PD patients in generalConclusions: The results of our post-hoc analysis show, that accessing PD patients in the last phase of their disease is extremely difficult and nearly fails in spite of an integrated care approach. Reasons for poor access and loss of follow-up at the end of life have to be identified and care models for PD patients until the end of life should be developed urgently.
000850854 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000850854 588__ $$aDataset connected to CrossRef
000850854 7001_ $$0P:(DE-HGF)0$$aDano, Richard$$b1
000850854 7001_ $$0P:(DE-HGF)0$$aSchill, Juliane$$b2
000850854 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b3
000850854 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b4
000850854 7001_ $$0P:(DE-HGF)0$$aVoltz, Raymond$$b5
000850854 7001_ $$0P:(DE-HGF)0$$aGolla, Heidrun$$b6
000850854 7001_ $$0P:(DE-HGF)0$$aLorenzl, Stefan$$b7
000850854 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2018.00627$$gVol. 9, p. 627$$p627$$tFrontiers in neurology$$v9$$x1664-2295$$y2018
000850854 8564_ $$uhttps://juser.fz-juelich.de/record/850854/files/fneur-09-00627.pdf$$yOpenAccess
000850854 8564_ $$uhttps://juser.fz-juelich.de/record/850854/files/fneur-09-00627.gif?subformat=icon$$xicon$$yOpenAccess
000850854 8564_ $$uhttps://juser.fz-juelich.de/record/850854/files/fneur-09-00627.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000850854 8564_ $$uhttps://juser.fz-juelich.de/record/850854/files/fneur-09-00627.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000850854 8564_ $$uhttps://juser.fz-juelich.de/record/850854/files/fneur-09-00627.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000850854 8564_ $$uhttps://juser.fz-juelich.de/record/850854/files/fneur-09-00627.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000850854 909CO $$ooai:juser.fz-juelich.de:850854$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000850854 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b3$$kFZJ
000850854 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000850854 9141_ $$y2018
000850854 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000850854 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000850854 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2015
000850854 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000850854 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000850854 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000850854 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000850854 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000850854 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000850854 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000850854 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000850854 920__ $$lyes
000850854 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000850854 980__ $$ajournal
000850854 980__ $$aVDB
000850854 980__ $$aUNRESTRICTED
000850854 980__ $$aI:(DE-Juel1)INM-3-20090406
000850854 9801_ $$aFullTexts